title: Hypothesis: Fingolimod explores new horizons in treatment of lymphoma.
abstract: Lymphomas (Hodgkin's (10%) and non-Hodgkin's (90%) lymphomas) are a group of blood cell tumors arising from lymphocytes and lymphadenopathy is the most common primary presentation of the disease. In non-Hodgkin lymphomas, the prognosis is worse. As the disease initiates, neoplastic cells may spread to and involve other lymph nodes and extra nodal regions. The disease is staged based on desperation of neoplastic cells and the prognosis highly depends on the stage of the disease at the time of diagnosis. Fingolimod is an immunomodulating drug, approved for treating relapsing forms of multiple sclerosis. Fingolimod impairs migration of lymphocytes from lymph nodes and it is hypothesized that Fingolimod could alleviate and decrease disease burden of lymphoma as it sequesters malignant cells within involved lymph nodes and it decelerates progression of the disease, increases efficacy of other treatment options and it is synergistic with anti-VEGF medications, it is an anti-metastatic, anti-inflammatory, cytostatic/cytotoxic agent and it boosts function of immune system in deterioration of neoplastic cells. Therefore, the agent can be used not only to treat lymphoma, but also to control and prevent relapse of the disease in those who are remitted.
authors.affiliation: Histomorphometry & Stereology Research Centre, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address: arsalan.azimi@gmail.com.
authors.forename: Arsalan
authors.initials: A
authors.lastname: Azimi
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage; D000068876:Fingolimod Hydrochloride / Q000008:administration & dosage*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007167:Immunotherapy / Q000379:methods; D008213:Lymphocyte Activation / Q000187:drug effects / Q000276:immunology*; D008223:Lymphoma / Q000188:drug therapy* / Q000276:immunology*; D018448:Models, Immunological
chemical_list: D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D000068876:Fingolimod Hydrochloride